1018448-65-1
中文名稱
曲妥珠單抗-美坦新偶聯物
英文名稱
Trastuzumab emtansine
CAS
1018448-65-1
更新日期
2026/07/16 12:18:39
基本信息
中文別名
曲妥珠單抗-美坦新偶聯物曲妥珠單抗-EMTANSINE偶聯物
曲妥珠單抗-美坦新偶聯物 (TDM-1)
英文別名
trastuzumab emtansineAdo-trastuzumab emtansine
Ado-trastuzuMab-eMtansine cas nr
Ado-trastuzumab Emtansine (TDM-1)
所屬類別
原料藥：抗腫瘤藥
曲妥珠單抗-美坦新偶聯物價格(試劑級)
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-P9921A | 曲妥珠單抗-美坦新偶聯物 Trastuzumab emtansine (solution) | 1018448-65-1 | 1 mg | 4800元 |
| 2026/06/05 | HY-P9921 | 曲妥珠單抗-美坦新偶聯物 Trastuzumab emtansine | 1018448-65-1 | 1mg | 4800元 |
| 2023/10/26 | HY-P9921 | 曲妥珠單抗-美坦新偶聯物 Trastuzumab emtansine | 1018448-65-1 | 5mg | 16000元 |
常見問題列表
生物活性
Trastuzumab emtansine (Ado-Trastuzumab emtansine) 是一種抗體偶聯藥物 (ADC)，其結合了 HER2 靶向的曲妥珠單抗的抗腫瘤特性以及微管抑制劑 DM1 的細胞毒活性。Trastuzumab emtansine 可用于晚期乳腺癌的研究。體外研究
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
體內研究
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice.
| Animal Model: | CB-17/SCID mice (6 weeks) were injected with OVA10 cells |
| Dosage: | 15 mg/kg |
| Administration: | I.v. three to five times weekly for 3 weeks |
| Result: | Showed remarkable inhibition of tumor growth in mice and was well tolerated. |